Slope Appoints Mark Melton as VP of Scientific Operations and Development
Founder of ClearPath Biomarker Ops joins Slope leadership team to expand the company's offerings to include biomarker operations and data management services
RICHMOND, Va., Sept. 28, 2023 /PRNewswire/ -- Slope, a global clinical trial technology company that specializes in complex, sample-intensive clinical trials, announced today that Mark Melton has joined the team as VP of Scientific Operations and Development. This leadership team expansion expedites Slope's delivery of a single complete solution for clinical trial execution from study start-up to study close, combining software with consultative services and support.
Melton brings deep scientific expertise having held leadership positions at Covance, Precision for Medicine, and Seagen, and most recently, as Founder and President of ClearPath Biomarker Ops, a consulting firm focused on optimizing biomarker operations and data management.
"Our goal is to provide a single, holistic clinical trial execution solution to the market," says Rust Felix, CEO at Slope. "Mark's addition will help us support critical study planning and operational decisions for our customers, while also improving the accuracy and efficiency of biomarker data collection and analysis, as well as sample reconciliation. This combined solution positions Slope as a valued partner throughout the entire study lifecycle."
In this role, Melton will build out Slope's consulting services specifically around study startup, biospecimen operations, data management, and study closeout. Additionally, Melton will leverage hs scientific expertise to support Slope's initiatives to tech-enable and automate many of these services, as well as lead efforts to grow relationships with global laboratories, and other third-party providers.
"I am excited to join Slope, and what this combined offering will mean for the industry," says Mark Melton, VP of Scientific Operations and Development at Slope. "I've dedicated my career to unifying biomarker scientific designs to the reality of running global trials. There hasn't been a solution to address the complex challenges across site, central, and third-party testing lab data and operations until now. I look forward to helping build on the company's momentum and provide sponsors with a holistic view of their biomarker and bioanalytical sample lifecycle and vendor operations."
"Mark is passionate about helping Slope streamline clinical research to help patients," says Hope Meely, Chief Clinical Officer at Slope. "We are excited to have him join the team to challenge the status quo, help sponsors navigate the complexities of sample management, and create market solutions that are both site and patient-focused."
This expansion in leadership and services aims to help Slope customers reduce sample collection, shipment, and processing issues, as well as site and vendor queries. The result is a more streamlined sample lifecycle, leading to higher quality biomarker and bioanalytical data, and preventing unnecessary study and regulatory submission delays.
For more information, visit slopeclinical.com
About Mark Melton:
View original content to download multimedia:https://www.prnewswire.com/news-releases/slope-appoints-mark-melton-as-vp-of-scientific-operations-and-development-301941087.html
IT Strategies for Multi-Generational Workforces
From Conversational AI to Generative AI
IDEA Showcase Startup Pitches & Reception